A research blog from the NCI Division of Cancer Prevention
Study With Common Pain Drug Shows Change in Immune Biomarkers, Highlights Pathway for Prevention of Colorectal Cancer in People with Lynch Syndrome
February 3, 2021 | By Susan JenksAn over-the-counter drug, readily available to consumers for years, may open a new option for preventing colorectal cancer in high-risk individuals.
It's not the mouse that roared but the quiet mouse behind the scenes that inspired researchers to look at the anti-inflammatory drug, naproxen, said Asad Umar, D.V.M., Ph.D., senior advisor to the director for translational research in the National Cancer Institute’s Division of Cancer Prevention and one of the study authors.
Scientific Achievements During 2020: An Unforgettable Year of Progress in the NCI Division of Cancer Prevention
December 17, 2020 | By Philip E. Castle, Ph.D., M.P.H.As this unforgettable year of 2020 comes to an end, I am reaching the milestone of my first 6 months as Director of the NCI Division of Cancer Prevention (DCP). It has been a whirlwind of virtual meetings and introductions. I remain humbled and honored by this opportunity to serve and to rejoin DCP with its rich history of leading cancer prevention science in the U.S. and globally.
DCP sponsors and directs groundbreaking, rigorous, collaborative research to revolutionize and accelerate prevention of cancer and its consequences. I am in awe of the breadth and depth of the division’s portfolio and excited to move forward our shared agenda in 2021. As cancer prevention researchers, our goal is to keep those who are healthy, healthy. Successful prevention is the absence of a cancer diagnosis, which is hard to see but critical to achieve. The best cancer is the cancer that never happens.
Making Informed Choices on Incorporating Chemoprevention Into Breast Care: Q & A with Dr. Katherine Crew on the MiCHOICE Trial
December 8, 2020 | By DCP StaffThe SWOG Cancer Research Network is opening to accrual the MiCHOICE Trial to study the use of decision support tools by women with high-risk breast conditions and their healthcare providers to choose among chemoprevention options. The MiCHOICE Trial was previously mentioned in the November 19 Cancer Prevention Science blog post How Patients and Their Doctors Determine Cancer Risk—and What Happens Next.
About 415 high-risk women and 200 healthcare providers will be enrolled through the NCI Community Oncology Research Program (NCORP) to the cluster randomized controlled trial. The estimated completion date is June 1, 2024. Katherine D. Crew, M.D., M.S., who is a Principal Investigator along with Rita Kukafka, Dr.P.H., M.A., answers a few questions.
How Patients and Their Doctors Determine Cancer Risk—and What Happens Next
November 19, 2020 | By Goli Samimi, Ph.D., M.P.H.If you were concerned that you might be at increased risk for a specific kind of cancer, what would you do to confirm that risk, and what would you be willing to do to reduce that risk? The answer is likely to be, "it depends on your doctor."
The ability to identify individuals at higher risk of cancer has significantly improved with technological and medical advances such as genetic testing and improved identification of precursor lesions. Individuals at higher risk for cancer are good candidates to potentially benefit from prevention interventions, including chemopreventive agents and risk-reducing surgery. However, studies have shown that acceptability, uptake, and adherence to preventive interventions is low, even among those at high risk of developing cancer.
Projects Making Progress in Breast Cancer Detection and Prevention
October 19, 2020 | By Philip E. Castle, Ph.D., M.P.H.In the month of October, breast cancer awareness is the health message that looms large. Yet, researchers across the National Cancer Institute and across the world are focused on breast cancer all the time. In the United States, more than 275,000 women are expected to be diagnosed with breast cancer this year and more than 3.5 million are breast cancer survivors.
The best breast cancer, however, is the one that never happens. That is where the prevention and detection research supported by the NCI Division of Cancer Prevention (DCP) is making a difference.
Research Issues in Gynecology and Women's Health: How do Benign Conditions Become Cancer?
September 28, 2020 | By Goli Samimi, Ph.D., M.P.H.Research to uncover how and why benign gynecologic conditions like endometriosis or uterine fibroids progress to invasive and deadly ovarian cancer or uterine sarcomas, is a critical and overlooked issue in women’s health. A new report on research priorities and an open funding opportunity are focused on addressing this issue.
In April 2019, Program Directors from the Division of Cancer Prevention and the Division of Cancer Biology within the National Cancer Institute (NCI) and the Gynecologic Health and Disease Branch within the National Institute of Child Health and Human Development (NICHD) organized a joint workshop with experts in benign and malignant gynecologic diseases to identify interesting and important research questions related to the biology, epidemiology and clinical characteristics involved in the processes by which gynecologic cancers progress from benign gynecologic conditions.
Smart Technology Is Aimed at Nutrition, Gut and Metabolism in Cancer Prevention Research Funding Opportunities
September 8, 2020 | By DCP StaffAs the availability and sophistication of smart technology for health (such as wearables, sensors, and micro-robotic tools) continues to increase, these devices could prove transformative in cancer prevention. Two ongoing Division of Cancer Prevention (DCP) funding opportunities are promoting the creation of smart devices to examine the interrelationships among nutrition, the gut microbiome, and human metabolism as tools for progress in cancer prevention research.
One DCP funding opportunity (PAR-20-133) seeks to examine the diet-host-microbiome interactions along the biogeography of the gastrointestinal (GI) tract using an ingestible micro-robotic pill. The other (PAR-20-134) focuses on the continuous monitoring of nutrients and their metabolites through wearable devices.
New Technology Gives Patients Access to a 5-Minute, Office-Based Test to Identify Risk for Esophageal Cancer
June 1, 2020 | By DCP StaffA new technology coupled with a new biomarker test now in clinical trials are giving patients timely access to a quick, accurate and less invasive way to identify risk for one type of esophageal cancer.
EsoCheck™ and EsoGuard™ are the device and test created for the detection of Barrett's esophagus, the benign and treatable precursor condition to esophageal adenocarcinomas (EAC). EAC are usually diagnosed at an advanced stage and are difficult to treat. Finding Barrett's esophagus, a sign of risk, could help patients by giving physicians a chance to intervene early. The technology was made more widely available with a special Food and Drug Administration (FDA) designation in February 2020.
Researchers Search the Genome for Clues to Early Age Onset Cancers in Racial/Ethnic Minorities
March 5, 2020 | By DCP StaffWhile researchers have identified some of the genetic changes that lead to cancer development, a key knowledge gap remains: finding the genetic changes that drive the development of cancers that arise at an earlier age than average (early onset) in racially and ethnically diverse populations. Compared to a White population, people who are Non-Hispanic Black, Hispanic, American Indian or Alaska Native are more likely to develop early age onset cancers and an overall higher incidence and mortality for breast, prostate, colorectal, liver, and kidney cancers, and for multiple myeloma. Although socioeconomic differences and availability of healthcare plays a factor in some health disparities, there are likely to be genetic differences as well.
Optimizing Clinical Interventions for Prevention of Cervical Cancer and HPV-related Cancers in People Living with HIV
February 3, 2020 | By Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.Cervical cancer is highly preventable, yet it is not fully prevented. Significant advancements in our understanding of the human papillomavirus (HPV)-linked development of cervical cancer have created highly effective clinical tools for primary prevention (HPV vaccines) and secondary prevention (screening and treatment of precancerous lesions). Despite this, more than half a million women are diagnosed and over 300,000 women die of cervical cancer every year globally.
Women with HIV have a three to five times higher risk of cervical cancer due to immunosuppression. Facing a dual burden of HIV disease and HPV/cervical cancer, these women are younger than the average age at cancer diagnosis. Their disease has a more aggressive clinical course and is less responsive to treatment. Access to affordable HIV treatment has expanded globally over the past several years, and millions of women living with HIV are living longer lives. Yet with the absence of efficient clinical prevention services, these women continue to be at risk of dying from cervical cancer. In addition to cervical cancer, people living with HIV are also at risk for other HPV-related cancers, including anal cancer, other lower genital tract cancers, and oropharyngeal cancers.